Last updated: April 3, 2026
What is NDC 73473-0500?
NDC 73473-0500 identifies Celidor (bempedoic acid) tablets manufactured by Esperion Therapies. Bempedoic acid is indicated as an adjunct for hypercholesterolemia or mixed dyslipidemia in patients who do not achieve LDL cholesterol (LDL-C) targets with statins alone.
Market Overview
Market Size and Demand
The global hypercholesterolemia treatment market was valued at approximately USD 7 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of around 8% through 2028. The segment including bempedoic acid is expected to expand due to the rising prevalence of cardiovascular disease, especially in aging populations.
Key market drivers:
- Increasing prevalence of hyperlipidemia
- Unmet needs in statin-intolerant patients
- Expanded indications and combination therapy options
Competitive Landscape
Bempedoic acid competes primarily with:
- Statins (e.g., atorvastatin, rosuvastatin)
- PCSK9 inhibitors (e.g., evolocumab, alirocumab)
- Other cholesterol-lowering agents (e.g., ezetimibe)
Bempedoic acid received FDA approval in February 2020 for use in adults with heterozygous familial hypercholesterolemia or established clinical atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering.
Major competitors' prices:
| Drug |
Weekly/Monthly Cost |
Class |
Key Differentiator |
| Evolocumab (Repatha) |
USD 1,500/month |
PCSK9 inhibitor |
Injectable, high efficacy |
| Rosuvastatin (Crestor) |
USD 0.15 per tablet |
Statin |
Widely prescribed, low cost |
| Ezetimibe (Zetia) |
USD 0.70 per tablet |
Cholesterol absorption inhibitor |
Often combined with statins |
| Bempedoic acid (NDC 73473-0500) |
USD 400–500/month |
ATP Citrate Lyase inhibitor |
Oral, moderate price point |
Pricing Trends and Factors
Pricing strategies for bempedoic acid vary by manufacturer, payer negotiations, and distribution channels. Launching prices ranged from USD 450 to USD 500 per month, positioning it above ezetimibe but below PCSK9 inhibitors.
Pricing is influenced by:
- High unmet clinical need
- Competitive therapies’ prices
- Cost-effectiveness analyses
- Payer coverage policies
Regulatory and Reimbursement Status
- FDA approval in February 2020
- CMS Medicare Part D coverage includes bempedoic acid as on-label for specific patient populations
- Payer reimbursement depends on formulary inclusion, with tiers affecting patient out-of-pocket costs
Price Projection Outlook (2023–2028)
Short-Term (2023–2025)
Initial prices will likely remain stable with incremental adjustments based on inflation and negotiation outcomes. Estimated average monthly price: USD 450–500.
Mid to Long-Term (2026–2028)
Pricing may decline modestly as generic options or biosimilars (if developed) enter the market or as newer therapies receive approval. Price reduction estimates: 10–15%, bringing drug costs to approximately USD 425–475 monthly.
Factors Impacting Price Trends
- Competitive pressure from PCSK9 inhibitors and combination pills
- Health care policy changes favoring lower-cost generic options
- Real-world evidence demonstrating clinical value and cost savings
Market Penetration and Revenue Projections
Assuming steady uptake:
| Year |
Estimated Patients |
Market Share |
Revenue (USD Million) |
| 2023 |
50,000 |
5% |
270 |
| 2024 |
100,000 |
8% |
540 |
| 2025 |
150,000 |
10% |
810 |
| 2026 |
200,000 |
12% |
960 |
| 2027 |
250,000 |
15% |
1,125 |
Note: projections assume incremental market adoption and stable pricing.
Key Takeaways
- NDC 73473-0500 (bempedoic acid) targets a growing hypercholesterolemia market with limited direct competitors besides ezetimibe and PCSK9 inhibitors.
- Launch prices around USD 450–500/month position it favorably but face pressure from generic cholesterol agents.
- Long-term price reductions are likely as market competition increases, with a mid-term decline estimate of approximately 10-15%.
- Revenue growth depends on uptake rates, payer coverage, and clinical adoption, with projections reaching over USD 1 billion annually by 2027 if market penetration progresses as anticipated.
FAQs
1. How does bempedoic acid differ from other cholesterol-lowering agents?
It is an oral inhibitor of ATP citrate lyase, which reduces LDL-C with a different mechanism than statins or PCSK9 inhibitors, and is indicated for patients intolerant to statins.
2. What is the typical pricing range for NDC 73473-0500?
The estimated monthly cost ranges from USD 450 to USD 500, depending on negotiations and payer policy.
3. How might future competitors impact its price?
Generic formulations or alternative therapies could drive prices downward by 10–15% over the next 3–5 years.
4. What are the primary markets for this drug?
The United States remains the largest market, with expansion into other developed markets as approval and reimbursement align.
5. Which factors influence the drug’s market share?
Clinical efficacy, safety profile, payer coverage, physician prescribing habits, and competitive pricing affect its market penetration.
References
- Grand View Research. (2022). Hypercholesterolemia Treatment Market Size, Share & Trends Analysis [Report].
- U.S. Food and Drug Administration. (2020). FDA Approves First New Cholesterol Lowering Drug in Over 20 Years.
- IQVIA. (2022). Monthly Cost Data for Cardiovascular Drugs.
- BlueCross BlueShield. (2022). Coverage Policies for Cholesterol-Lowering Medications.
- MarketWatch. (2023). Prognosis and Future Outlook for Hyperlipidemia Drugs.
